Changing epidemiology of candidaemia in Australia

Belinda Chapman; Monica Slavin; Debbie Marriott; Catriona Halliday; Sarah Kidd; Ian Arthur; Narin Bak; Christopher H. Heath; Karina Kennedy; C. Orla Morrissey; Tania C. Sorrell; Sebastian van Hal; Caitlin Keighley; Emma Goeman; Neil Underwood; Krispin Hajkowicz; Ann Hofmeyr; Michael Leung; Nenad Macesic; Jeannie Botes; Christopher Blyth; Louise Cooley; C. Robert George; Pankaja Kalukottege; Alison Kesson; Brendan McMullan; Robert Baird; Jennifer Robson; Tony M. Korman; Stella Pendle; Kerry Weeks; Eunice Liu; Elaine Cheong; Sharon Chen; on behalf of the Australian and New Zealand Mycoses Interest Group; M. Thomas; S. M. Bell; C. Marshall

doi:10.1093/jac/dkw422

Changing epidemiology of candidaemia in Australia

Belinda Chapman, Monica Slavin, Debbie Marriott, Catriona Halliday, Sarah Kidd, Ian Arthur, Narin Bak, Christopher H. Heath, Karina Kennedy, C. Orla Morrissey, Tania C. Sorrell, Sebastian van Hal, Caitlin Keighley, Emma Goeman, Neil Underwood, Krispin Hajkowicz, Ann Hofmeyr, Michael Leung, Nenad Macesic, Jeannie BotesChristopher Blyth, Louise Cooley, C. Robert George, Pankaja Kalukottege, Alison Kesson, Brendan McMullan, Robert Baird, Jennifer Robson, Tony M. Korman, Stella Pendle, Kerry Weeks, Eunice Liu, Elaine Cheong, Sharon Chen, on behalf of the Australian and New Zealand Mycoses Interest Group, M. Thomas, S. M. Bell, C. Marshall

Research output: Contribution to journal › Article › peer-review

131 Citations (Scopus)

Abstract

Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOne^TM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/10⁵ population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

Original language	English
Pages (from-to)	1103-1108
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	72
Issue number	4
DOIs	https://doi.org/10.1093/jac/dkw422
Publication status	Published - Apr 2017
Externally published	Yes

Keywords

antifungal agents
epidemiology
azoles
candida albicans
candida parapslosis
candida tropicalis

Access to Document

10.1093/jac/dkw422Licence: In Copyright

Cite this

Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., Sorrell, T. C., van Hal, S., Keighley, C., Goeman, E., Underwood, N., Hajkowicz, K., Hofmeyr, A., Leung, M., Macesic, N., ... Marshall, C. (2017). Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy, 72(4), 1103-1108. https://doi.org/10.1093/jac/dkw422

@article{f6321e7ef2ba4af1bd0c61c1d9b8ddd1,

title = "Changing epidemiology of candidaemia in Australia",

abstract = "Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.",

keywords = "antifungal agents, epidemiology, azoles, candida albicans, candida parapslosis, candida tropicalis",

author = "Belinda Chapman and Monica Slavin and Debbie Marriott and Catriona Halliday and Sarah Kidd and Ian Arthur and Narin Bak and Heath, {Christopher H.} and Karina Kennedy and Morrissey, {C. Orla} and Sorrell, {Tania C.} and {van Hal}, Sebastian and Caitlin Keighley and Emma Goeman and Neil Underwood and Krispin Hajkowicz and Ann Hofmeyr and Michael Leung and Nenad Macesic and Jeannie Botes and Christopher Blyth and Louise Cooley and George, {C. Robert} and Pankaja Kalukottege and Alison Kesson and Brendan McMullan and Robert Baird and Jennifer Robson and Korman, {Tony M.} and Stella Pendle and Kerry Weeks and Eunice Liu and Elaine Cheong and Sharon Chen and {on behalf of the Australian and New Zealand Mycoses Interest Group} and K. Daveson and H. Wilson and M. Thomas and G. Peachey and T. Gottlieb and E. Lui and F. Jozwiak and Bell, {S. M.} and V. Menon and G. Kotsiou and C. Marshall and C. Ferguson and M. Bryant and C. Reed and J. Darvall and V. Maddigan and P. Boan",

year = "2017",

month = apr,

doi = "10.1093/jac/dkw422",

language = "English",

volume = "72",

pages = "1103--1108",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "4",

}

Chapman, B, Slavin, M, Marriott, D, Halliday, C, Kidd, S, Arthur, I, Bak, N, Heath, CH, Kennedy, K, Morrissey, CO, Sorrell, TC, van Hal, S, Keighley, C, Goeman, E, Underwood, N, Hajkowicz, K, Hofmeyr, A, Leung, M, Macesic, N, Botes, J, Blyth, C, Cooley, L, George, CR, Kalukottege, P, Kesson, A, McMullan, B, Baird, R, Robson, J, Korman, TM, Pendle, S, Weeks, K, Liu, E, Cheong, E, Chen, S, on behalf of the Australian and New Zealand Mycoses Interest Group, Thomas, M, Bell, SM & Marshall, C 2017, 'Changing epidemiology of candidaemia in Australia', Journal of Antimicrobial Chemotherapy, vol. 72, no. 4, pp. 1103-1108. https://doi.org/10.1093/jac/dkw422

TY - JOUR

T1 - Changing epidemiology of candidaemia in Australia

AU - Chapman, Belinda

AU - Slavin, Monica

AU - Marriott, Debbie

AU - Halliday, Catriona

AU - Kidd, Sarah

AU - Arthur, Ian

AU - Bak, Narin

AU - Heath, Christopher H.

AU - Kennedy, Karina

AU - Morrissey, C. Orla

AU - Sorrell, Tania C.

AU - van Hal, Sebastian

AU - Keighley, Caitlin

AU - Goeman, Emma

AU - Underwood, Neil

AU - Hajkowicz, Krispin

AU - Hofmeyr, Ann

AU - Leung, Michael

AU - Macesic, Nenad

AU - Botes, Jeannie

AU - Blyth, Christopher

AU - Cooley, Louise

AU - George, C. Robert

AU - Kalukottege, Pankaja

AU - Kesson, Alison

AU - McMullan, Brendan

AU - Baird, Robert

AU - Robson, Jennifer

AU - Korman, Tony M.

AU - Pendle, Stella

AU - Weeks, Kerry

AU - Liu, Eunice

AU - Cheong, Elaine

AU - Chen, Sharon

AU - on behalf of the Australian and New Zealand Mycoses Interest Group

AU - Daveson, K.

AU - Wilson, H.

AU - Thomas, M.

AU - Peachey, G.

AU - Gottlieb, T.

AU - Lui, E.

AU - Jozwiak, F.

AU - Bell, S. M.

AU - Menon, V.

AU - Kotsiou, G.

AU - Marshall, C.

AU - Ferguson, C.

AU - Bryant, M.

AU - Reed, C.

AU - Darvall, J.

AU - Maddigan, V.

AU - Boan, P.

PY - 2017/4

Y1 - 2017/4

N2 - Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

AB - Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

KW - antifungal agents

KW - epidemiology

KW - azoles

KW - candida albicans

KW - candida parapslosis

KW - candida tropicalis

UR - http://www.scopus.com/inward/record.url?scp=85018362721&partnerID=8YFLogxK

U2 - 10.1093/jac/dkw422

DO - 10.1093/jac/dkw422

M3 - Article

C2 - 28364558

AN - SCOPUS:85018362721

SN - 0305-7453

VL - 72

SP - 1103

EP - 1108

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 4

ER -

Changing epidemiology of candidaemia in Australia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this